探讨人附睾蛋白(HE)4和CA₁₂₅联合检测在卵巢癌诊断中的应用价值，以及HE4水平与卵巢癌病理学分型的相关性。

选择2013年12月至2014年2月在河南省商丘市第一人民医院住院拟接受手术治疗的137例卵巢肿瘤患者为研究对象，根据术后病理检查结果将其分为卵巢癌组(n＝54)和卵巢良性肿瘤组(n＝83)。选择同期于本院体检中心体检且体检结果健康的76例女性纳入对照组，分别采用酶联免疫吸附法和电化学发光免疫分析法对3组受试者的血清HE4和CA₁₂₅水平进行测定，并对检测结果进行统计学分析。本研究卵巢癌组及卵巢良性肿瘤组纳入标准：盆、腹腔影像学检查发现卵巢部位包块者；排除标准：排除相关检查发现子宫内膜异位症及盆腔炎症，合并原发性高血压、糖尿病等慢性疾病及肝、肾、心功能异常者，相关检查发现其他部位肿瘤及存在家族肿瘤病史的患者。3组受试者年龄构成比比较，差异无统计学意义(P>0.05)。本研究遵循的程序符合河南省商丘市第一人民医院人体试验委员会制定的伦理学标准，得到该委员会批准，分组征得受试对象及监护人知情同意，并与监护人签署临床研究知情同意书。

卵巢癌组患者血清HE4及CA₁₂₅水平分别为(335.25±314.02) pmol/L、(2215.25±1234.71)U/mL，显著高于卵巢良性肿瘤组的(45.36±8.14)pmol/L及(34.26±9.25)U/mL与对照组的(44.16±6.33) pmol/L及(27.85±8.25)U/mL，差异均有统计学意义(t＝12.351，12.407，16.124，15.426；P<0.01)。CA₁₂₅和HE4联合检测，对诊断卵巢癌的敏感度均显著高于二者单项检测，且差异均有统计学意义(t＝4.788，3.927；P<0.05)。

血清HE4和CA₁₂₅联合检测极大地提高了对卵巢癌诊断的敏感度，对卵巢良、恶性肿瘤的鉴别诊断具有重要意义。

To explore the application value of human epididymis protein (HE)4 and carbohydrate antigen 125 (CA₁₂₅) joint detection in the diagnosis of ovarian cancer and the correlation between HE4 level and pathological types of ovarian cancer.

From December 2013 to February 2014, a total of 137 cases of inpatients with ovarian tumor who would receive operation in Shangqiu First People's Hospital in Henan Province were selected into this study. According to the postoperative pathological examination results, they were divided into ovarian cancer group (n=54) and benign tumor group (n=83). During the same period 76 cases of health women who took health examination in the same hospital were selected as control group. The levels of serum HE4 and CA₁₂₅ in three groups were respectively measured by enzyme linked immunosorbent assay and electro chemiluminescence immunoassay, and the testing results were statistically analyzed. The inclusion criteria of ovarian cancer group and benign tumor group in this study: confirmed by chest X-ray and ultrasonography, there was no tumor in other parts of the body; the exclusion criteria: patients with endometriosis and pelvic inflammatory disease detected by related examinations were excluded, and complicated with essential hypertension, diabetes and other chronic diseases, with liver, renal or cardiac dysfunction, and with tumors in other parts of the body and family history of cancer were excluded. The difference in age structure of the three groups was not statistically significant (P>0.05). The procedure that this study followed met the ethical standards made by Institutional Review Board of Shangqiu First People's Hospital in Henan Province and approved by the committee. Grouping had the consent of study subjects, and the clinical study letters of consent were signed.

The serum HE4 and CA₁₂₅ levels in the ovarian cancer group were (335.25±314.02)pmol/L and (2215.25±1234.71)U/mL, respectively, which were significantly higher than those(45.36±8.14)pmol/L and (34.26±9.25)U/mL in benign tumor group, and (44.16±6.33)pmol/L, (27.85±8.25)U/mL in control group, and the differences were statistically significant (t=12.351, 12.407, 16.124, 15.426; P<0.01). The sensitivity of HE4 and CA₁₂₅ joint detection in the diagnosis of ovarian cancer was higher than that CA₁₂₅ or HE4 detection alone, and the differences were statistically significant (t=4.788, 3.927; P<0.05).

The joint detection of serum HE4 and CA₁₂₅ significantly improves the sensitivity in diagnosis of ovarian cancer, which is of great significance to the differential diagnosis of benign and malignant ovarian tumors.